Rajnikant Kothari, MD
Psychiatry · Massillon, OHNPI 1710942982
Payments from drug & device makers
Across 741 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$903
- AbbVie$898
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$1,0699%
- Food & beverage$11,41091%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 77 | $2,257 |
| Teva Pharmaceuticals USA, Inc. | 121 | $1,918 |
| Alkermes, Inc. | 95 | $1,542 |
| Vanda Pharmaceuticals Inc. | 76 | $1,373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $903 |
| AbbVie(2 entities) | 77 | $898 |
| Bausch Health US, LLC | 57 | $835 |
| Lundbeck LLC | 39 | $593 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $363 |
| Axsome Therapeutics, Inc. | 24 | $309 |
| Exact Sciences | 16 | $270 |
| Johnson & Johnson | 16 | $256 |
| Neurocrine Biosciences, Inc. | 14 | $217 |
| Almatica Pharma LLC | 9 | $157 |
| Jazz Pharmaceuticals Inc. | 7 | $114 |
| Shire North American Group Inc | 6 | $86 |
| Adlon Therapeutics L.p. | 6 | $82 |
| Neos Therapeutics, LP | 5 | $64 |
| Eisai Inc. | 3 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| Merck | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Validus Pharmaceuticals LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Corium, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$1,069
How this compares
$12,490 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $136,967 |
| AplenzinBupropion Hbr | 13 | $77,624 |
| TrintellixVortioxetine Hydrobromide | 124 | $66,574 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,662 |
| RexultiBrexpiprazole | 12 | $17,373 |
| Lamictal OdtLamotrigine | 11 | $11,584 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $9,728 |
| Lurasidone Hcl | 90 | $9,359 |
| Vilazodone Hcl | 99 | $9,011 |
| Bupropion XlBupropion Hcl | 580 | $8,100 |
| Lamotrigine OdtLamotrigine | 19 | $7,544 |
| XanaxAlprazolam | 11 | $5,818 |
| Lamotrigine | 723 | $5,757 |
| Duloxetine Hcl | 305 | $4,654 |
| Paliperidone ErPaliperidone | 12 | $4,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,918 | $136,96713 claims |
| Bausch Health US, LLCAplenzin | $835 | $77,62413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $903 | $76,303150 claims |
| Alkermes, Inc.Lybalvi | $1,542 | $19,66212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Massillon
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.